Literature DB >> 16328012

Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1.

Susanne Voelter-Mahlknecht1, Ulrich Mahlknecht.   

Abstract

Sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, which belongs to the silent information regulator 2 (Sir2) family of sirtuin histone deacetylases (HDACs). The yeast Sir2 protein and its mammalian derivatives play a central role in epigenetic gene silencing, DNA repair and recombination, cell-cycle, microtubule organization, and in the regulation of aging. We have isolated and characterized the human Sirt1 genomic sequence, which spans a region of 33,660 bp and which has one single genomic locus. Determination of the exon-intron splice junctions established that SIRT1 is encoded by 9 exons ranging in size from 80 bp (exon 6) to 2,120 bp (exon 9). Characterization of the 5' flanking genomic region, which precedes the Sirt1 open reading frame, revealed a CCAAT-box and a number of NF-kappaB and GATA transcription factor binding sites in addition to a small 350 bp CpG island. The 4,107 bp human Sirt1 mRNA has an open reading frame of 2,244 bp and encodes a 747 aa protein with a predictive molecular weight of 81.7 kDa and an isoelectric point of 4.55. Fluorescence in situ hybridization analysis localized the human Sirt1 gene to chromosome 10q21.3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16328012

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  21 in total

1.  Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer.

Authors:  Minqing Wu; Weidong Wei; Xiangsheng Xiao; Jiaoli Guo; Xinhua Xie; Laisheng Li; Yanan Kong; Ning Lv; Weihua Jia; Yin Zhang; Xiaoming Xie
Journal:  Med Oncol       Date:  2012-06-04       Impact factor: 3.064

Review 2.  Genetic studies reveal the role of the endocrine and metabolic systems in aging.

Authors:  Nir Barzilai; Ilan Gabriely; Gil Atzmon; Yousin Suh; Devorah Rothenberg; Aviv Bergman
Journal:  J Clin Endocrinol Metab       Date:  2010-10       Impact factor: 5.958

Review 3.  Sirtuin 1: A Target for Kidney Diseases.

Authors:  Lili Kong; Hao Wu; Wenhua Zhou; Manyu Luo; Yi Tan; Lining Miao; Lu Cai
Journal:  Mol Med       Date:  2015-01-12       Impact factor: 6.354

Review 4.  Resveratrol Boosts Cognitive Function by Targeting SIRT1.

Authors:  Wenyan Cao; Ying Dou; Aiping Li
Journal:  Neurochem Res       Date:  2018-06-25       Impact factor: 3.996

5.  Clinicopathological and prognostic role of SIRT1 in breast cancer patients: a meta-analysis.

Authors:  Yu-Wen Cao; Yu-Cong Li; Guo-Xing Wan; Xiao-Ming Du; Feng Li
Journal:  Int J Clin Exp Med       Date:  2015-01-15

6.  Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1.

Authors:  Bixi Jian; Shaolong Yang; Irshad H Chaudry; Raghavan Raju
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

7.  Sirtuin1 expression predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.

Authors:  Masatomo Teramae; Takeshi Fukuda; Takuma Wada; Masaru Kawanishi; Kenji Imai; Makoto Yamauchi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Mol Clin Oncol       Date:  2014-09-24

8.  Expression of the significance of silent information regulator type-1 in Angioimmunoblastic T-cell lymphoma is greater association with tumorigenesis and has strong implications for adverse prognosis.

Authors:  Yuyue Ren; Yunhe Gu; Wei Wang; Jinghua Wang; Xiaoyun Li; Ying Wang; Haiyan Gao; Xiushuai Dong; Yaoyao Tian
Journal:  Cell Cycle       Date:  2016-04-28       Impact factor: 4.534

9.  The expression levels of the sirtuins in patients with BCC.

Authors:  Metin Temel; Mustafa Nihat Koç; Saffet Ulutaş; Bülent Göğebakan
Journal:  Tumour Biol       Date:  2015-12-02

Review 10.  Sirtuin-1 regulation of mammalian metabolism.

Authors:  Matthew P Gillum; Derek M Erion; Gerald I Shulman
Journal:  Trends Mol Med       Date:  2011-01       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.